BRPI0606774A2 - método para o tratamento de um paciente humano que tem carcinoma de célula renal e uso de il-2 - Google Patents

método para o tratamento de um paciente humano que tem carcinoma de célula renal e uso de il-2

Info

Publication number
BRPI0606774A2
BRPI0606774A2 BRPI0606774-3A BRPI0606774A BRPI0606774A2 BR PI0606774 A2 BRPI0606774 A2 BR PI0606774A2 BR PI0606774 A BRPI0606774 A BR PI0606774A BR PI0606774 A2 BRPI0606774 A2 BR PI0606774A2
Authority
BR
Brazil
Prior art keywords
cell carcinoma
renal cell
treating
human patient
therapy
Prior art date
Application number
BRPI0606774-3A
Other languages
English (en)
Inventor
Laurence Elias
Gary Witherell
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of BRPI0606774A2 publication Critical patent/BRPI0606774A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

MéTODO PARA O TRATAMENTO DE UM PACIENTE HUMANO QUE TEM CARCINOMA DE CéLULA RENAL E USO DE IL-2. São revelados métodos para o tratamento de carcinoma de célula renal que usam baixas doses de IL-2. Em particular, a invenção relaciona-se a métodos de tratamento de carcinoma de célula renal metastático em pacientes que têm insuficiência renal e/ou intolerantes à terapia com alta dose de IL-2. O regime terapêutico aqui descrito inibe de forma significativa o crescimento do tumor com toxicidade e efeitos colaterais adversos reduzidos comparado à terapia com alta dose de IL-2.
BRPI0606774-3A 2005-01-27 2006-01-27 método para o tratamento de um paciente humano que tem carcinoma de célula renal e uso de il-2 BRPI0606774A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64749605P 2005-01-27 2005-01-27
PCT/US2006/003116 WO2006081510A2 (en) 2005-01-27 2006-01-27 Methods for treating renal cell carcinoma

Publications (1)

Publication Number Publication Date
BRPI0606774A2 true BRPI0606774A2 (pt) 2009-07-14

Family

ID=36741121

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606774-3A BRPI0606774A2 (pt) 2005-01-27 2006-01-27 método para o tratamento de um paciente humano que tem carcinoma de célula renal e uso de il-2

Country Status (13)

Country Link
US (2) US20070014765A1 (pt)
EP (1) EP1846020B1 (pt)
JP (2) JP2008528621A (pt)
KR (1) KR20070102576A (pt)
CN (1) CN101132809A (pt)
AU (1) AU2006207987B2 (pt)
BR (1) BRPI0606774A2 (pt)
CA (1) CA2595959A1 (pt)
ES (1) ES2432141T3 (pt)
IL (1) IL184865A (pt)
MX (1) MX2007009012A (pt)
RU (1) RU2404795C2 (pt)
WO (1) WO2006081510A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110243851A1 (en) * 2008-12-11 2011-10-06 Agency For Science, Technology And Research Glucose-peg conjugates for reducing glucose transport into a cell
US20150299255A1 (en) * 2010-11-01 2015-10-22 Susavion Biosciences, Inc. Compositions and methods for modulating innate and adaptive immune systems
EP3211001B1 (en) 2010-12-22 2020-10-07 The Board of Trustees of the Leland Stanford Junior University Superagonists and antagonists of interleukin-2
ES2811624T3 (es) * 2011-03-11 2021-03-12 Hopitaux Paris Assist Publique Régimen de dosificación de IL-2 para tratar lupus eritematoso sistémico
JP2016533167A (ja) 2013-09-24 2016-10-27 メディシナ セラピューティクス ピーティーイー リミテッド インターロイキン−２融合タンパク質及びその使用
CN106659757B (zh) 2014-04-24 2022-01-28 利兰斯坦福初级大学董事会 白介素2的超级激动剂、部分激动剂和拮抗剂
KR20170035910A (ko) 2014-08-11 2017-03-31 데리니아, 인크. 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 변형된 il-2 변이체
CA2983666C (en) * 2015-04-27 2021-07-27 Susavion Biosciences, Inc. Compositions and methods for treating cancer and persistent viral infections
US10350260B2 (en) * 2015-04-27 2019-07-16 Susavion Biosciences, Inc. Compositions and methods for treating cancer and persistent viral infections
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
WO2018089420A1 (en) 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases
CU24483B1 (es) * 2016-11-15 2020-04-02 Ct Inmunologia Molecular Método para incrementar los niveles de secreción de la interleucina-2
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
WO2018217989A1 (en) 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
EP3641814A4 (en) 2017-06-19 2021-06-23 Medicenna Therapeutics Inc. USES AND METHODS FOR IL-2 SUPERAGONISTS, AGONISTS, AND FUSIONS THEREOF
TWI821192B (zh) 2017-07-11 2023-11-11 美商新索思股份有限公司 非天然核苷酸之導入及其方法
AR112969A1 (es) 2017-08-03 2020-01-15 Synthorx Inc Conjugados de citoquina para el tratamiento de enfermedades proliferativas e infecciosas
EP3713592A4 (en) * 2017-11-21 2022-01-12 The Board of Trustees of the Leland Stanford Junior University INTERLEUKIN-2 PARTIAL AGONISTS
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
MA54952A (fr) 2019-02-06 2022-05-11 Synthorx Inc Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
KR20220035333A (ko) 2019-05-20 2022-03-22 팬디온 오퍼레이션스, 인코포레이티드 Madcam 표적 면역관용
TW202136316A (zh) 2019-12-20 2021-10-01 美商再生元醫藥公司 新穎之il2促效劑及其使用方法(一)
EP4087865A2 (en) 2020-01-10 2022-11-16 Bright Peak Therapeutics AG Modified il-2 polypeptides and uses thereof
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752585A (en) * 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
AU2003280442B2 (en) * 2002-07-01 2009-02-05 Wilex Ag Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas

Also Published As

Publication number Publication date
US8012465B2 (en) 2011-09-06
CN101132809A (zh) 2008-02-27
RU2007132125A (ru) 2009-03-10
WO2006081510A3 (en) 2007-01-18
ES2432141T3 (es) 2013-11-29
EP1846020A2 (en) 2007-10-24
WO2006081510A2 (en) 2006-08-03
MX2007009012A (es) 2007-09-14
KR20070102576A (ko) 2007-10-18
IL184865A (en) 2011-04-28
US20070014765A1 (en) 2007-01-18
US20100316595A1 (en) 2010-12-16
AU2006207987B2 (en) 2011-09-15
CA2595959A1 (en) 2006-08-03
JP2012046552A (ja) 2012-03-08
AU2006207987A1 (en) 2006-08-03
RU2404795C2 (ru) 2010-11-27
EP1846020B1 (en) 2013-08-21
IL184865A0 (en) 2007-12-03
JP2008528621A (ja) 2008-07-31

Similar Documents

Publication Publication Date Title
BRPI0606774A2 (pt) método para o tratamento de um paciente humano que tem carcinoma de célula renal e uso de il-2
Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials
Belani et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non–small-cell lung cancer
BRPI0409919A (pt) combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
BRPI0406667A (pt) Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg
BRPI0517976A (pt) métodos de tratamento
DK1169059T3 (da) Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
Rampino et al. Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
Adışen et al. Ultraviolet A1 phototherapy in the treatment of early mycosis fungoides
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
MX2021009051A (es) Tratamiento de lesiones cutaneas y prurito en pacientes con prurigo nodular.
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
WO2005113720A3 (en) A strategy for designing patient-specific anti-cancer drugs
Magno et al. Double-blind randomized study of lonidamine and radiotherapy in head and neck cancer
Marcenaro et al. Ablative or palliative stereotactic body radiotherapy with helical tomotherapy for primary or metastatic lung tumor
EA201270298A1 (ru) Способ лечения злокачественной опухоли
WO2006124573A3 (en) Treatment of cancer with 2-deoxyglucose
Neu et al. Radiotherapy for Prevention and Therapy of Gynecomastia Due to Antiandrogen Treatment in Prostate Cancer Patients
Stellamans et al. Does sucralfate reduce early side effects of pelvic radiation? A double-blind randomized trial
Wrenn et al. A Phase I Study using low-dose fractionated whole abdominal radiotherapy as a chemopotentiator to full-dose cisplatin for optimally debulked stage III/IV carcinoma of the endometrium
MX2023001140A (es) Uso del dexpramipexol para el tratamiento de asma moderado a grave.
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
TW200501958A (en) A therapeutic agent for treating a behavioral disorder

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]